Treatment of spontaneous pyometra in 22 bitches with a combination of cabergoline and cloprostenol.
Twenty-two bitches with ultrasonographically diagnosed spontaneous pyometra were treated with a combination of 5 microg/kg cabergoline per day and 5 mug/kg cloprostenol every third day, and potentiated sulphonamide twice a day. Bitches with either open-cervix or closed-cervix pyometra showed a rapid clinical improvement, associated with a reduction in plasma progesterone concentration, increased vulval discharge and a reduction in the diameter of the uterus. The haematological profiles of 21 of the bitches returned to normal within six days of treatment, and their biochemical profiles returned to normal within nine days; 19 of the bitches were managed successfully by a 10-day period of treatment. Two bitches required a further three days of treatment, and in one bitch with a partial uterine torsion the treatment was not successful. Adverse effects of the treatment were limited to the 60 minutes immediately after the administration of prostaglandin, and included retching, vomiting, mild abdominal straining, diarrhoea and panting. The incidence of adverse effects was reduced after each successive dose of prostaglandin. Eleven of the 21 successfully treated bitches were mated at the next oestrus, and seven became pregnant; their litters were smaller than the published breed averages. In four of the bitches the pyometra recurred after the next oestrus.
England
G C W
GC
School of Veterinary Medicine and Science, University of Nottingham, Sutton Bonington Campus, Loughborough, Leicestershire LE12 5RD, UK.
Freeman
S L
SL
Russo
M
M
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000077465:Cabergoline; D003008:Cloprostenol / Q000008:administration & dosage*; D004283:Dog Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004359:Drug Therapy, Combination; D004714:Endometrial Hyperplasia / Q000188:drug therapy / Q000662:veterinary*; D004873:Ergolines / Q000008:administration & dosage*; D005260:Female; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014463:Ultrasonography
D000970:Antineoplastic Agents; D004873:Ergolines; D003008:Cloprostenol; D000077465:Cabergoline